PAUL NUGENT
- Type
- Physician · Allopathic & Osteopathic Physicians / Family Medicine
- Where
- FT WRIGHT, KY
- NPI
- 1932157435
- Received
- $158,104 in 20 records, 2019 to 2025 ($2,309 general, $155,795 research)
- As principal investigator
- $4,914,356 of research payments to others in 7,597 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 5 | $2,309 |
| 2022 | Research payment | 5 | $153,501 |
| 2020 | Research payment | 1 | $1,505 |
| 2019 | Research payment | 9 | $789 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Valneva Austria GmbH | 4 | $153,373 | 2022 |
| ModernaTX, Inc. | 5 | $2,309 | 2023 |
| Eli Lilly and Company | 2 | $1,633 | 2020–2022 |
| ABBVIE INC. | 9 | $789 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 15 | $155,795 |
| Travel and Lodging | 4 | $1,898 |
| Food and Beverage | 1 | $411 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-01-19 | ModernaTX, Inc. | $1,227 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-01-19 | ModernaTX, Inc. | $411 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-01-19 | ModernaTX, Inc. | $267 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-01-19 | ModernaTX, Inc. | $247 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-01-19 | ModernaTX, Inc. | $155 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2022-08-15 | Valneva Austria GmbH | $35,266 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L | 2022 | |
| 2022-04-29 | Eli Lilly and Company | $128 | Research payment | In-kind items and services | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2022 | |
| 2022-03-28 | Valneva Austria GmbH | $36,742 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L | 2022 | |
| 2022-03-14 | Valneva Austria GmbH | $51,719 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L | 2022 | |
| 2022-03-14 | Valneva Austria GmbH | $29,644 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L | 2022 | |
| 2020-06-29 | Eli Lilly and Company | $1,505 | Research payment | In-kind items and services | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2020 | |
| 2019-07-10 | ABBVIE INC. | $32 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
| 2019-07-10 | ABBVIE INC. | $23 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
| 2019-04-05 | ABBVIE INC. | $273 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
| 2019-04-05 | ABBVIE INC. | $58 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
| 2019-04-05 | ABBVIE INC. | $36 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
| 2019-04-05 | ABBVIE INC. | $18 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
| 2019-04-05 | ABBVIE INC. | $18 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
| 2019-04-04 | ABBVIE INC. | $204 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
| 2019-04-04 | ABBVIE INC. | $124 | Research payment | In-kind items and services | Androgel Drug, Endocrinology | M16-100 | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-18 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $1,226 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-12-18 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $1,284 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-11-27 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $1,896 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-11-18 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $3,443 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-10-31 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $1,206 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-09-24 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $631 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2025 |
| 2025-09-17 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $842 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2025 |
| 2025-07-26 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $1,250 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2025 |
| 2025-07-18 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $55,267 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2025 |
| 2025-06-10 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $20,433 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-06-09 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $10,500 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-05-21 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $29,963 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-04-21 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $50,386 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-04-08 | VERTEX PHARMACEUTICALS INCORPORATED | SYNEXUS CLINICAL RESEARCH CINCINNATI | $19,122 | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Assoc | 2025 |
| 2025-03-14 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $729 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-03-12 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $96,308 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-03-07 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $1,584 | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I | 2025 |
| 2025-02-24 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $350,141 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a C | 2025 |
| 2025-01-13 | Novartis Pharmaceuticals Corporation | SYNEXUS CLINICAL RESEARCH | $18,862 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | SYNEXUS CLINICAL RESEARCH CINCINNATI | $104,872 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine | 2025 |
| 2024-12-31 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $421 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-12-10 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $8,605 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-11-26 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $9,564 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-11-08 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $8,289 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-11-01 | VERTEX PHARMACEUTICALS INCORPORATED | SYNEXUS CINCINNATI | $22,126 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine | 2024 |
| 2024-10-21 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $191 | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I | 2024 |
| 2024-10-05 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $6,099 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-09-11 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $31,864 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-08-28 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $7,748 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-08-06 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $31,638 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-06-05 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $12,725 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-05-29 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $42 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-05-24 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $74,540 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-05-01 | Novavax Inc | SYNEXUS CLINICAL RESEARCH US INC | $250 | A 2-PART, PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A SARS-CoV-2 RECOMB | 2024 |
| 2024-04-25 | Novartis Pharmaceuticals Corporation | SYNEXUS CLINICAL RESEARCH | $27,510 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-04-24 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $42 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-04-15 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $293 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-04-05 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $17,620 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-03-28 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $26,430 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-03-27 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $8,151 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-03-08 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $33,555 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-02-27 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $84,834 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-02-24 | VERTEX PHARMACEUTICALS INCORPORATED | SYNEXUS CINCINNATI | $443 | Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) | 2024 |
| 2024-02-14 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $2,433 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-02-13 | PFIZER INC. | SYNEXUS CLINICAL RESEARCH US INC | $9,481 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-02-07 | ABBVIE INC. | SYNEXUS CLINICAL RESEARCH US INC | $2,250 | A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( | 2024 |
| 2024-02-07 | ABBVIE INC. | SYNEXUS CLINICAL RESEARCH US INC | $325 | A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( | 2024 |
| 2024-02-01 | PFIZER INC. | Synexus Clinical Research US Cincinnati | $4,266 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 |
| 2024-01-31 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $1,500 | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I | 2024 |
| 2023-12-12 | PFIZER INC. | Synexus Clinical Research US Inc Synexus Clinical Research US Inc | $997 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2023 |
| 2023-12-12 | PFIZER INC. | Synexus Clinical Research US Inc Synexus Clinical Research US Inc | $63 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2023 |
| 2023-11-30 | PFIZER INC. | Synexus Clinical Research US Cincinnati | $403 | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2023 |
| 2023-11-16 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $789 | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I | 2023 |
| 2023-11-10 | SANOFI PASTEUR INC. | Clinical Research Advantage,inc | $5,354 | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I | 2023 |
| 2023-11-08 | ABBVIE INC. | SYNEXUS CLINICAL RESEARCH US INC | $259 | A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe | 2023 |
| 2023-10-19 | ABBVIE INC. | SYNEXUS CLINICAL RESEARCH US INC | $150 | A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe | 2023 |
| 2023-10-18 | Rhythm Pharmaceuticals, Inc. | Synexus Clinical Research US, Inc. | $1,826 | RM-493-022 | 2023 |
| 2023-10-17 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $441 | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I | 2023 |
| 2023-10-12 | ABBVIE INC. | SYNEXUS CLINICAL RESEARCH US INC | $519 | A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe | 2023 |
| 2023-10-06 | SANOFI PASTEUR INC. | Clinical Research Advantage,inc | $5,678 | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I | 2023 |
| 2023-09-15 | GlaxoSmithKline, LLC. | SYNEXUS CLINICAL RESEARCH US INC | $499 | A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT | 2023 |
| 2023-08-28 | SANOFI PASTEUR INC. | Clinical Research Advantage Inc | $6,264 | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and I | 2023 |
| 2023-08-23 | GlaxoSmithKline, LLC. | SYNEXUS CLINICAL RESEARCH US INC | $499 | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | 2023 |
| 2023-07-20 | ABBVIE INC. | SYNEXUS CLINICAL RESEARCH US INC | $75 | A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe | 2023 |
| 2023-07-11 | ABBVIE INC. | SYNEXUS CLINICAL RESEARCH US INC | $1,760 | A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe | 2023 |
| 2023-06-28 | GlaxoSmithKline, LLC. | SYNEXUS CLINICAL RESEARCH US INC | $1,000 | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | 2023 |
| 2023-06-28 | GlaxoSmithKline, LLC. | SYNEXUS CLINICAL RESEARCH US INC | $6,000 | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | 2023 |
| 2023-06-28 | GlaxoSmithKline, LLC. | SYNEXUS CLINICAL RESEARCH US INC | $3,500 | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | 2023 |
| 2023-06-27 | Novartis Pharmaceuticals Corporation | SYNEXUS CLINICAL RESEARCH | $6,709 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-06-21 | GlaxoSmithKline, LLC. | SYNEXUS CLINICAL RESEARCH US INC | $499 | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | 2023 |
| 2023-06-20 | Janssen Research & Development, LLC | Optimal Research, LLC | $14,205 | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | 2023 |
| 2023-06-08 | ABBVIE INC. | SYNEXUS CLINICAL RESEARCH US INC | $3,594 | A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $706 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $100 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
| 2023-05-30 | ModernaTX, Inc. | AES Cincinnati (DRS) | $100 | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immuno | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Fort Wright, KY, county Kenton County, KY, state Kentucky; placed by its city name.
| Measure | Place (city or town) Fort Wright, KY | County Kenton County, KY | State Kentucky |
|---|---|---|---|
| Population B01003 | 5,887 | 171,288 | 4,534,824 |
| Population, 2020 census P1 | 5,851 | 169,064 | 4,505,836 |
| Median age B01002 | 37.5 | 37.7 | 39.1 |
| Under 18 B01001 | 20.2% | 23.3% | 22.6% |
| 65 and over B01001 | 20.3% | 15.7% | 17.3% |
| Households B11001 | 2,315 | 67,367 | 1,814,469 |
| Foreign born B05002 | 7.4% | 4.1% | 4.7% |
| Median household income B19013 | $105,024 | $80,548 | $63,726 |
| Median family income B19113 | $128,036 | $103,206 | $81,505 |
| Per capita income B19301 | $44,173 | $43,733 | $35,821 |
| Poverty rate B17001 | 3.0% | 11.8% | 16.1% |
| Unemployment rate B23025 | 3.4% | 4.3% | 4.9% |
| Civilian labor force B23025 | 3,247 | 92,927 | 2,152,038 |
| Mean commute (minutes) B08013 | 19.5 | 22.3 | 24.0 |
| Bachelor's degree or higher B15003 | 45.3% | 37.4% | 27.6% |
| Housing units B25001 | 2,425 | 73,221 | 2,023,116 |
| Owner-occupied B25003 | 70.7% | 70.7% | 68.3% |
| Renters B25003 | 29.3% | 29.3% | 31.7% |
| Median home value B25077 | $328,900 | $244,400 | $205,600 |
| Median gross rent B25064 | $1,142 | $1,069 | $967 |
| White, not Hispanic B03002 | 84.5% | 85.2% | 81.5% |
| Black B03002 | 1.7% | 3.9% | 7.6% |
| Hispanic or Latino B03002 | 5.9% | 4.9% | 5.0% |
| Asian B03002 | 0.2% | 1.1% | 1.6% |
| American Indian and Alaska Native B03002 | 0.5% | 0.1% | 0.1% |
Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Fort Wright, KY.
Comments